Hydrafacial Results Presentation Deck

Q4 2022 balance sheet highlights Cash and cash equivalents Warrants Convertible debt Revolving credit facility Shares outstanding 25 → Approximately $568.2 million cash and cash equivalents on balance sheet Approximately 7.0 million Private Warrants outstanding $750.0 million 1.25% convertible notes due 2026 → Use of proceeds: capped call transaction, potential future acquisitions, working capital expenditures, and general corporate purposes → Conversion price of $31.76; capped call agreement provides dilution protection up to $47.94 $50.0 million Senior Secured Credit Facility remains undrawn; current undrawn commitment fee of 25 bps Allows flexibility for future M&A; ex-US operations unencumbered; convertible debt excluded from covenants → Approximately 132.2 million current shares outstanding First $100 million accelerated share repurchase program completed; approximately 9.3 million shares retired → Second $100 million accelerated share repurchase program expected to be completed by the end of Q2 2023 BEAUTYHEALTH™

View entire presentation